Hyperthyroidism medications

Hyperthyroidism medications


0 / 14 complete


0 / 2 complete
High Yield Notes
6 pages

Hyperthyroidism medications

14 flashcards

and methimazole are two hyperthyroidism medications that can cause agranulocytosis and aplastic anemia.


USMLE® Step 1 style questions USMLE

2 questions

USMLE® Step 2 style questions USMLE

1 questions

An 18-year-old woman comes to the clinic because of tachycardia, nervousness, decreased exercise tolerance, and weight loss over the past 6 months. She was previously healthy and takes no medications. Her sister has Graves disease. Her pulse is 124/min, respirations are 18/min, and blood pressure is 128/78 mm Hg. Her BMI is 19 kg/m2. There is no proptosis. Examination of the neck shows a smooth and enlarged thyroid gland. Cardiac examination shows regular tachycardia. Her lungs are clear to auscultation. Laboratory studies are obtained and show:

Thyroid-stimulating hormone: <0.01 µU/mL Thyroxine (T4 ): 15.5 μg/dLTriiodothyronine (T3 ): 240 ng/L 

Which of the following is the most appropriate treatment for this patient?

External References

Content Reviewers:

Rishi Desai, MD, MPH

In hyperthyroidism, ‘hyper’ refers to having too much, and ‘thyroid’ refers to thyroid hormones, so hyperthyroidism refers to a condition where there’s excess thyroid hormones.

Medications used to treat hyperthyroidism either reduce the level of thyroid hormones or treat the symptoms by targeting the affected tissue.

There are 2 different thyroid hormones; triiodothyronine or T3, and thyroxine or T4.

Now, if we zoom into the thyroid gland, we’ll find thousands of follicles, which are small, hollow spheres whose walls are lined with follicular cells, or thyrocytes.

Zooming further into these follicular cells, we’ll see their apical side that surrounds a central lumen filled with a viscous fluid called the colloid.

The colloid contains the precursor hormone thyroglobulin.

The basolateral side of follicular cells is in contact with blood vessels that supply these cells.

Synthesis of thyroid hormones begins when follicular cells take in inorganic iodide ions from the blood, along with two sodium ions, via a sodium- iodide symporter.

This step is known as ‘iodide trap’.

The iodide ion is pumped via the pendrin protein, into the viscous fluid inside the follicle called the colloid, which contains thyroglobulin; the precursor of thyroid hormone.

In the colloid, inorganic iodide undergoes oxidation via the enzyme thyroid peroxidase or TPO, to become organic iodide, which then binds to the tyrosine in thyroglobulin.

This step is known as iodination.

Some tyrosine residues bind to only one iodine and form monoiodotyrosine or MIT, whereas others bind to two iodine atoms to form diiodotyrosine or DIT.

These molecules are then coupled together by the same enzyme thyroid peroxidase.

This process is known as coupling.

Coupling one MIT with one DIT creates T3, while coupling 2 DIT molecules creates T4.

T4 is generally created in greater amounts than T3, with T3 being the more active form with a half life of 1 to 2 days, while T4 is less active but has a longer half life of 6 to 8 days.

Once released from the thyroid gland, most of the T3 and T4 travels via the blood by binding with the thyroxine - binding globulin, or TBG, to reach the target cell.

Alternatively, small amounts of T3 and T4 stay unbound, and therefore they are referred to as “free” thyroid hormones.

Only “free” thyroid hormones are physiologically active because they are able to enter the cell.

Now, once inside the cell, T4 is mostly converted into T3 by the enzyme 5’- deiodinase. T3 binds to thyroid hormone receptors which are within the cell’s nucleus, and these receptors regulate gene expression, which ultimately lead to various metabolic and physiologic effects in the body.

This increase in metabolism uses up sugars and fats for energy and produces more body heat.

Thyroid hormones also help activate the sympathetic nervous system which is responsible for the fight or flight response.

This increases heart rate and cardiac output, respiratory rate, and mental alertness.

Thyroid hormones also increase the gastrointestinal or GI motility and they are necessary for normal neuronal development in growing fetuses and young children.

Now, hyperthyroidism can happen in a few different ways.

The most common cause is Graves’ disease, an autoimmune disorder where B cells produce autoantibodies against thyroid stimulating hormone receptors on follicular cells.

These autoantibodies bind to the receptors and activate them, which causes the thyroid follicles to grow and produce more thyroid hormones.

One complication is Graves’ ophthalmopathy which is inflammation and edema in the tissue around the eyes, causing the eyeball to be displaced forwards, eyelids to retract and giving the eyes a “bulging” appearance.

Other disorders like toxic multinodular goiter and thyroiditis can also cause increased release of thyroid hormones.

Now, the symptoms of hyperthyroidism include weight loss despite an increase in appetite because of the higher basal metabolic rate; heat intolerance because the body is producing more heat; and rapid heart rate or tachycardia, sweating, hyperactivity, anxiety and insomnia because of the effect of thyroid hormones on the sympathetic nervous system.

Untreated hyperthyroidism combined with a stressor like an infection or illness can trigger a life- threatening complication called thyroid storm.

Many of the symptoms of hyperthyroidism then become exaggerated, leading to severe tachyarrhythmia, high fever, delirium, and coma.

Now, there are several classes of medications to control hyperthyroidism.

First, we can target the thyroid gland itself, and either decrease the synthesis of thyroid hormones or prevent them from being released.

The other option, at the target tissue peripherally; is to decrease the effectiveness of the thyroid hormones; this only manages the symptoms but doesn’t treat the cause.

Let’s start with the radioactive iodine therapy, also known as “radioiodine ablation therapy”.

The isotope of iodine that is used is I131 .

It’s taken peroral and eventually gets taken up by the thyroid.

Over the course of a few weeks, the radioactive isotope collects in the colloid and emits beta radiation that causes permanent damage to the thyroid.

This is the definitive treatment for hyperthyroidism caused by Graves’ disease and toxic multinodular goiter, but it could also worsen Graves’ ophthalmopathy.

Since the thyroid is permanently destroyed, the person will need to take thyroid hormone replacements like levothyroxine to prevent hypothyroidism.

Radioactive iodine crosses the placenta and is secreted in breast milk, so it should be avoided in people who are pregnant or breastfeeding.

Therefore, administration of radioactive iodine to childbearing individuals requires a negative pregnancy test!

Finally, as far as side effects go, radioactive iodide can cause infertility, thyroiditis, and radiation toxicity, such as neoplasia, hematopoietic suppression, and salivary and lacrimal toxicity.

Next, we have thioamides, which include propylthiouracil, or PTU, and methIMAzole.

Both of these medications are given perorally and are absorbed by the thyroid where they inhibit thyroid peroxidase.

This stops the oxidation of iodide ions into organic iodine, the iodination of tyrosine residues in thyroglobulin, and the coupling of MIT and DIT to form T3 and T4.

It’s important to note that these medications do not inhibit the release of thyroid hormones; therefore they require several weeks until the thyroid depletes its storage of hormones to manifest their therapeutic effect.

In addition, PTU also works in the peripheral tissue by inhibiting 5’- deiodinase to block the conversion of T4 into T3, which makes it the preferred medication during thyroid storms.

  1. "Katzung & Trevor's Pharmacology Examination and Board Review,12th Edition" McGraw-Hill Education / Medical (2018)
  2. "Rang and Dale's Pharmacology" Elsevier (2019)
  3. "Goodman and Gilman's The Pharmacological Basis of Therapeutics, 13th Edition" McGraw-Hill Education / Medical (2017)
  4. "Hyperthyroidism: Diagnosis and Treatment" Am Fam Physician (2016)
  5. "Subclinical Hyperthyroidism: When to Consider Treatment" Am Fam Physician (2017)
  6. "Hyperthyroidism" The Lancet (2016)
  8. "Increased cancer incidence after radioiodine treatment for hyperthyroidism" Cancer (2007)
  9. "Lugol’s solution and other iodide preparations: perspectives and research directions in Graves’ disease" Endocrine (2017)